
CLAIMS

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising an anticancer agent and a protective agent according to Formula 1,



Formula 1

wherein:

X^1 is CR^5R^6, NR^5, O, S, C=O, or C=S;


each of R^1, R^2, R^3, R^5, R^6, R^9, and R^{10} is independently alkyl, alkenyl, alkynyl, alkoxy, acyl, acyloxy, carboxylic acid, ester, amine, amide, carbonate, carbamate, nitro, thioether, thioester, cycloalkyl, heteroalkyl, heterocyclyl, aryl, or heteroaryl, any of which is substituted or unsubstituted, halogen, hydroxyl, sulfhydryl, nitro, nitroso, cyano, azido, or H;

R^4, R^7 and R^8 are alkoxy, hydroxyl or H;

W^1 is O or S; or

a salt thereof.

2. The pharmaceutical composition of claim 1, wherein the protective agent is myricetin and is a compound according to the following formula:



3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a tablet.
4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is liquid.
5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a capsule, a gel capsule, or a liposome.
6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least 10 mg of the protective agent.
7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least 50 mg of the protective agent.
8. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least 100 mg of the protective agent.
9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least 200 mg of the protective agent.
10. The pharmaceutical composition of claim 1, wherein the anticancer agent is doxorubicin.
11. A compound of Formula I according to Claim 1 for use in the treatment of anthracycline–induced cardiotoxicity, wherein the compound of Formula I is to be administered to a subject in combination with anthracycline or a salt thereof.
12. The compound of claim 11, wherein the anthracycline is doxorubicin.
13. The compound of claim 12, wherein the compound of Formula I is myricetin.
14. The compound of claim 13, wherein the compound is to be administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 48 hours before the administration of the anthracycline to the subject.
15. The compound of claim 13, wherein the compound is to be administered concurrently with the anthracycline to the subject.

16. Use of a compound of Formula I according to Claim 1 in the manufacture of a medicament for the treatment of anthracycline–induced cardiotoxicity, wherein the compound of Formula I is to be administered to a subject in combination with anthracycline or a salt thereof.

17. The use of claim 16, wherein the anthracycline is doxorubicin.

18. The use of claim 17, wherein the compound of Formula I is myricetin.

19. The use of claim 18, wherein the compound is to be administered at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 48 hours before the administration of the anthracycline to the subject.

20. The use of claim 18, wherein the compound is to be administered concurrently with the anthracycline to the subject.